A profile of delafloxacin in the treatment of adults with community-acquired bacterial pneumonia

References

• Fry AM, Shay DK, Holman RC, et al. Trends in hospitalizations for pneumonia among persons aged 65 years or older in the United States, 1988-2002. JAMA. 2005;294(21):2712–2719.
   Google Scholar
• Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–79.
   Google Scholar
• Tichopad A, Roberts C, Gembula I, et al. Clinical and economic burden of community-acquired pneumonia among adults in Czech Republic, Hungary, Poland and Slovakia. PLOS ONE. 2013;8(8):e71375.
   Google Scholar
• World Health Organization. Global Health Estimates; 2019 [cited 2021 Dec 12]. Available from: https://www.who.int/gard/publications/The_Global_Impact_of_Respiratory_Disease.pdf
   Google Scholar
• GBD. 2019 diseases and injuries collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019. Lancet. 2020;396(10258):1204–1222.
   Google Scholar
• Jain S, Self WH, Wunderink RG, et al. CDC EPIC study team. Community- acquired pneumonia requiring hospitalization among U.S. Adults. N Engl J Med. 2015;373:415–427.
   Google Scholar
• Carugati M, Aliberti S, Sotgiu G, et al., Bacterial etiology of community-acquired pneumonia in immunocompetent hospitalized patients and appropriateness of empirical treatment recommendations: an international point-prevalence study. Eur J Clin Microbiol Infect Dis. 39(8): 1513–1525. 2020.
   Google Scholar
• Arnold FW, Summersgill JT, Lajoie AS, et al. Community-Acquired Pneumonia Organization (CAPO) investigators. A worldwide perspective of atypical pathogens in community-acquired pneumonia. Am J Respir Crit Care Med. 2007;175(10):1086–1093.
   Google Scholar
• Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010;50(2):202–209.
   Google Scholar
• Marik PE. Aspiration pneumonitis and aspiration pneumonia. N Engl J Med. 2001;344:665–671.
   Google Scholar
• Mandell LA, Niederman MS. Aspiration pneumonia. N Engl J Med. 2019 14;380(7):651–663.
   Google Scholar
• WHO. Coronavirus Disease. (COVID-2019) Situation report. Geneva; 2021 [cited 2021 Dec 12]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/situation-reports
   Google Scholar
• Woodhead M, Blasi F, Ewig S, et al., European Respiratory Society; European Society of Clinical Microbiology and Infectious Diseases. Guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2005;26(6):1138–1180.
   Google Scholar
• Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American thoracic society and infectious diseases Society of America. Am J Respir Crit Care Med. 2019;200(7):e45–e67.
   Google Scholar
• Ahronheim GA, Reich B, Marks MI. Penicillin-insensitive pneumococci. Case report and review. Am J Dis Child. 1979;133(2):187–191.
   Google Scholar
• Gartner JC, Michaels RH. Meningitis from a pneumococcus moderately resistant to penicillin. JAMA. 1979 Apr 20;241(16):1707–1709.
   Google Scholar
• Mace JW, Janik DS, Sauer RL, et al. Penicillin-resistant pneumococcal meningitis in an immunocompromised infant. J Pediatr. 1977;91(3):506–507.
   Google Scholar
• Lonks JR, Garau J, Gomez L, et al. Failure of macrolide antibiotic treatment in patients with bacteremia due to erythromycin-resistant Streptococcus pneumoniae. Clin Infect Dis. 2002;35(5):556–564.
   Google Scholar
• Dylewski J, Davidson R. Bacteremic pneumococcal pneumonia associated with macrolide failure. Eur J Clin Microbiol Infect Dis. 2006;25(1):39–42.
   Google Scholar
• Shindo Y, Ito R, Kobayashi D, et al. Risk factors for drug-resistant pathogens in community-acquired and healthcare-associated pneumonia. Am J Respir Crit Care Med. 2013;188(8):985–995.
   Google Scholar
• Hidron AI, Low CE, Honig EG, et al. Emergence of community-acquired meticillin-resistant Staphylococcus aureus strain USA300 as a cause of necrotising community-onset pneumonia. Lancet Infect Dis. 2009;9(6):384–392.
   Google Scholar
• Lam AP, Wunderink RG. The role of MRSA in healthcare-associated pneumonia. Semin Respir Crit Care Med. 2009;30(1):52–60.
   Google Scholar
• Hageman JC, Uyeki TM, Francis JS, et al. Severe community-acquired pneumonia due to Staphylococcus aureus, 2003-04 influenza season. Emerg Infect Dis. 2006;12(6):894–899.
   Google Scholar
• European Centre for Disease Prevention and Control. 2020 Surveillance of antimicrobial resistance in the European Union (EU)/European Economic Area (EAA), (EARS-Net). Stockholm:ECDC; 2021 [cited 2021 Dec 19]. Available from: https://atlas.ecdc.europa.eu/public/index.aspx?Dataset=27&HealthTopic=4
   Google Scholar
• Centers for Disease Control and Prevention (CDC). CDC’s 2019 antibiotic resistance threats report. [cited 2021 Dec 19]. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/strep-pneumoniae-508.pdf
   Google Scholar
• Aliberti S, Reyes LF, Faverio P, et al. GLIMP investigators. Global initiative for meticillin-resistant Staphylococcus aureus pneumonia (GLIMP): an international, observational cohort study. Lancet Infect Dis. 2016;16(12):1364–1376.
   Google Scholar
• File TM, Low DE, Eckburg PB, et al. FOCUS 1: a randomized, double blinded, multicentre, Phase III trial of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in community-acquired pneumonia. J Antimicrob Chemother. 2011;66(suppl 3):iii19–iii32.
   Google Scholar
• Nicholson SC, Welte T, File TM, et al. A randomised, double blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012;39:240–246.
   Google Scholar
• File TM, Goldberg L, Das A, et al. Efficacy and safety of IV-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis. 2019;69:1856–1867.
   Google Scholar
• Macone AB, Caruso BK, Leahy RG, et al. In vitro and in vivo antibacterial activities of omadacycline, a novel aminomethylcycline. Antimicrob Agents Chemother. 2014;8:1127–1135.
   Google Scholar
• Ramirez J, Deck DH, Eckburg PB, et al. Efficacy of omadacycline versus moxifloxacin in the treatment of community-acquired bacterial pneumonia by disease severity: results from the OPTIC study. Open Forum Infect Dis. 2021;8(6):ofab135.
   Google Scholar
• Nascimento-Carvalho CM. Delafloxacin as a treatment option for community-acquired pneumonia infection. Expert Opin Pharmacother. 2021;22(15):1975–1982.
   Google Scholar
• Mogle BT, Steele JM, Thomas SJ, et al. Clinical review of delafloxacin: a novel anionic fluoroquinolone. J Antimicrob Chemother. 2018 Jun 1;73(6):1439–1451.
   Google Scholar
• Saravolatz LD, Stein GE. Delafloxacin: a new anti-methicillin-resistant staphylococcus aureus fluoroquinolone. Clin Infect Dis. 2019;68(6):1058–1062.
   Google Scholar
• Remy JM, Tow-Keogh CA, McConnell TS, et al. Activity of delafloxacin against methicillin-resistant Staphylococcus aureus: resistance selection and characterization. J Antimicrob Chemother. 2012;67(12):2814–2820.
   Google Scholar
• Pfaller MA, Sader HS, Rhomberg PR, et al., In vitro activity of delafloxacin against contemporary bacterial pathogens from the United States and Europe, 2014. Antimicrob Agents Chemother. 2017;61(4):e02609–16.
   Google Scholar
• Flamm RK, Rhomberg PR, Huband MD, et al. In vitro activity of delafloxacin tested against isolates of streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. Antimicrob Agents Chemother. 2016;60:6381–6385.
   Google Scholar
• Hammerschlag MR, Roblin PM. The in vitro activity of a new fluoroquinolone, ABT-492, against recent clinical isolates of Chlamydia pneumoniae. J Antimicrob Chemother. 2004;54:281–282.
   Google Scholar
• Waites KB, Crabb DM, Duffy LB. Comparative in vitro susceptibilities and bactericidal activities of investigational fluoroquinolone ABT-492 and other antimicrobial agents against human mycoplasmas and ureaplasmas. Antimicrob Agents Chemother. 2003;47:3973–3975.
   Google Scholar
• Nilius AM, Shen LL, Hensey-Rudloff D, et al. In vitro antibacterial potency and spectrum of ABT-492, a new fluoroquinolone. Antimicrob Agents Chemother. 2003;47(10):3260–3269.
   Google Scholar
• Iregui A, Khan Z, Saquib M, et al. Emergence of delafloxacin-resistant in Staphylococcus aureus in Brooklyn New York. Clin Infect Dis. 2020;70(8):1758–1760.
   Google Scholar
• Sillerström E, Wahlund E, Nord CE. In vitro activity of ABT-492 against anaerobic bacteria. J Chemother. 2004;16(3):227–229.
   Google Scholar
• Soge OO, Salipante SJ, No D, et al. In vitro activity of delafloxacin against clinical Neisseria gonorrhoeae Isolates and selection of gonococcal delafloxacin resistance. Antimicrob Agents Chemother. 2016;60(5):3106–3111.
   Google Scholar
• Wright DH, Brown GH, Peterson ML, et al. Application of fluoroquinolone pharmacodynamics. J Antimicrob Chemother. 2000;46(5):669–683.
   Google Scholar
• Jorgensen SCJ, Mercuro NJ, Davis SL, et al. Delafloxacin: place in therapy and review of microbiologic, clinical and pharmacologic properties. Infect Dis Ther. 2018;7(2):197–217.
   Google Scholar
• Thabit AK, Crandon JL, Nicolau DP. Pharmacodynamic and pharmacokinetic profiling of delafloxacin in a murine lung model against community-acquired respiratory tract pathogens. Int J Antimicrob Agents. 2016;48(5):535–541. .
   Google Scholar
• Lepak AJ, Andes DR. In vivo pharmacodynamic target assessment of delafloxacin against staphylococcus aureus, streptococcus pneumoniae, and Klebsiella pneumoniae in a murine lung infection model. Antimicrob Agents Chemother. 2016;60(8):4764–4769.
   Google Scholar
• Bortolon E, Molstad D, Remy J, et al. In vivo PK/PD of delafloxacin against Escherichia coli and Pseudomonas aeruginosa in the mouse thigh infection model. Poster session presented at: the ASM Microbe; 2017 Jun 15–17; New Orleans, LA, USA.
   Google Scholar
• Bauer J, Siala W, Tulkens PM, et al. A combined pharmacodynamic quantitative and qualitative model reveals the potent activity of daptomycin and delafloxacin against Staphylococcus aureus biofilms. Antimicrob Agents Chemother. 2013;57(6):2726–2737.
   Google Scholar
• Lemaire S, Tulkens PM, Van Bambeke F. Contrasting effects of acidic pH on the extracellular and intracellular activities of the anti-gram-positive fluoroquinolones moxifloxacin and delafloxacin against Staphylococcus aureus. Antimicrob Agents Chemother. 2011 Feb;55(2):649–658.
   Google Scholar
• Ding Y, Villet RA, Lee JC, et al. Treatment of renal abscesses caused by Staphylococcus aureus MW2, using delafloxacin and moxifloxacin. Poster presented at: 21st European Congress of Clinical Microbiology and Infectious Diseases; 2011 May 7–10; Milan, Italy.
   Google Scholar
• Hoover R, Hunt T, Benedict M, et al., Safety, tolerability, and pharmacokinetic properties of intravenous delafloxacin after single and multiple doses in healthy volunteers. Clin Ther. 2016;38(1):53–65.
   Google Scholar
• Hoover R, Hunt T, Benedict M, et al., Single and multiple ascending-dose studies of oral delafloxacin: effects of food, sex, and age. Clin Ther. 2016;38(1):39–52.
   Google Scholar
• Wu K, Yan Z. Clinical pharmacology and biopharmaceutical review. Delafloxacin. NDA#208610, 208611. In: Melinta therapeutics, inc. division of anti-infective products. Center for Drug Evaluation and Research. US Food and Drug Administration; 2017.
   Google Scholar
• Parra-Ruiz J, Hernández-Quero J. Pharmacodynamic and pharmacokinetic evaluation of respiratory fluoroquinolones. Guideline to selection of the most appropriate fluoroquinolone. Rev Esp Quimioter. 2012;25(4):245–251.
   Google Scholar
• Baxdela (delafloxacin) [Package Insert]. Lincolnshire IL: Melinta Therapeutics Inc; 2017 [cited 2021 Dec 11]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/208610s000,208611s000lbl.pdf
   Google Scholar
• McEwen A, Lawrence L, Hoover R, et al., Disposition, metabolism and mass balance of delafloxacin in healthy human volunteers following intravenous administration. Xenobiotica. 2015;45(12):1054–1062.
   Google Scholar
• Paulson SK, Wood-Horrall RN, Hoover R, et al. The pharmacokinetics of the CYP3A substrate midazolam after steady-state dosing of delafloxacin. Clin Ther. 2017;39:1182–1190.
   Google Scholar
• Hoover R, Marbury TC, Preston RA, et al. Clinical pharmacology of delafloxacin in patients with hepatic impairment. J Clin Pharmacol. 2017;57:328–335.
   Google Scholar
• Hoover R, H A Jr, Lawrence L, et al. Delafloxacin pharmacokinetics in subjects with varying degrees of renal function. J Clin Pharm. 2018;58:514–521.
   Google Scholar
• Hoover R, H A Jr, Lawrence L, et al. Pharmacokinetics of intravenous delafloxacin in patients with end-stage renal disease. J Clin Pharmacol. 2018;58(7):913–919.
   Google Scholar
• Litwin JS, Benedict MS, Thorn MD, et al. A thorough QT study to evaluate the effects of therapeutic and supratherapeutic doses of delafloxacin on cardiac repolarization. Antimicrob Agents Chemother. 2015;59:3469–3473.
   Google Scholar
• Ferguson J DRS, Ibbotson S, Ibbotson S, et al. Lack of phototoxicity potential with delafloxacin in healthy male and female subjects: comparison to lomefloxacin. Photochem Photobiol Sci. 2018;17(6):773–780.
   Google Scholar
• Longcor J, Hopkins S, Wikler M, et al. A phase 2 safety and efficacy study of oral delafloxacin in subjects with acute bacterial exacerbation of chronic bronchitis (ABECB). Presented at: ID Week; San Diego, CA; 2012 Oct 17–21 [cited 2021 Dec 12]; Available from: https://idsa.confex.com/idsa/2012/webprogram/Paper37662
   Google Scholar
• Millar BC, McCaughan J, Rendall JC, et al. Delafloxacin–A novel fluoroquinolone for the treatment of ciprofloxacin-resistant Pseudomonas aeruginosa in patients with cystic fibrosis. Clin Respir J. 2021 Jan;15(1):116–120.
   Google Scholar
• Longcor J, Hopkins S, Wikler M, et al. A phase 2 study of the safety and efficacy of oral delafloxacin (DLX) in community acquired pneumonia (CAP). Presented at: ID Week; San Diego, CA; 2012 Oct 17–21 [cited 2021 Dec 12]. Available from: https://idsa.confex.com/idsa/2012/webprogram/Paper37662
   Google Scholar
• O’Riordan W, Mehra P, Manos P, et al. A randomized phase 2 study comparing two doses of delafloxacin with tigecycline in adults with complicated skin and skin-structure infections. Int J Infect Dis. 2015;30:67–73.
   Google Scholar
• Kingsley J, Mehra P, Lawrence LE, et al. A randomized, double-blind, phase 2 study to evaluate subjective and objective outcomes in patients with acute bacterial skin and skin structure infections treated with delafloxacin, linezolid or vancomycin. J Antimicrob Chemother. 2016;71(3):821–829.
   Google Scholar
• Horcajada JP, Salata RA, Álvarez-Sala R, et al., A phase 3 study to compare delafloxacin with moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Open Forum Infect Dis. 2019;7(1):ofz514.
   Google Scholar
• McCurdy S, Keedy K, Lawrence L, et al. Efficacy of delafloxacin versus moxifloxacin against bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): microbiology results from the delafloxacin phase 3 CABP trial. Antimicrob Agents Chemother. 2020;64:e01949–19.
   Google Scholar
• McCurdy S, Nenninger A, Sheets A, et al. Efficacy of delafloxacin versus moxifloxacin against atypical bacterial respiratory pathogens in adults with community-acquired bacterial pneumonia (CABP): data from the delafloxacin phase 3 CABP trial. Int J Infect Dis. 2020;97:374.
   Google Scholar
• Pullman J, Gardovskis J, Farley B, PROCEED Study Group, et al. Efficacy and safety of delafloxacin compared with vancomycin plus aztreonam for acute bacterial skin and skin structure infections: a Phase 3, double-blind, randomized study. J Antimicrob Chemother. 2017;72:3471–3480.
   Google Scholar
• O’Riordan W, McManus A, Teras J, PROCEED Study Group, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;675:657–666.
   Google Scholar
• Hook EW, Golden MR, Taylor SN, et al. Efficacy and safety of single-dose oral delafloxacin compared with intramuscular ceftriaxone for uncomplicated gonorrhea treatment: an open-label, noninferiority, phase 3, multicenter, randomized study. Sex Transm Dis. 2019 May;46(5):279–286.
   Google Scholar
• Lodise T, Corey R, Hooper D, et al., Safety of delafloxacin: focus on adverse events of special interest. Open Forum Infect Dis. 2018;5(10): ofy220.
   Google Scholar
• Lee CC, Lee MT, Chen YS, et al. Risk of aortic dissection and aortic aneurysm in patients taking oral fluoroquinolone. JAMA Intern Med. 2015;175:1839–1847.
   Google Scholar
• U.S. Food and Drug Administration. Drug Safety Communication: FDA warns about increased risk of ruptures or tears in the aorta blood vessel with fluoroquinolone antibiotics in certain patients. 2018 Dec 20 [cited 2021 Dec 12]. Available from: https://www.fda.gov/Drugs/DrugSafety/ucm628753.htm.opens/in/new/tab
   Google Scholar
• Pasternak B, Inghammar M, Svanström H. Fluoroquinolone use and risk of aortic aneurysm and dissection: nationwide cohort study. BMJ. 2018;360:k678.
   Google Scholar
• European Medicines Agency. Fluoroquinolone and quinolone antibiotics: PRAC recommends restrictions on use (Europa.eu) New restrictions follow review of disabling and potentially long-lasting side effects. EMA/668915/2018; 2018 Oct 5 [cited 2021 Dec 12]. Available from: https://www.ema.europa.eu/en/documents/press-release/fluoroquinolone-quinolone-antibiotics-prac-recommends-restrictions-use_en.pdf
   Google Scholar
• European Medicines Agency. Summary of risk management plan for quofenix (delafloxacin).[cited 2021 Dec 12]. Available from: https://www.ema.europa.eu/en/documents/rmp-summary/quofenix-epar-risk-management-plan-summary_pdf
   Google Scholar
• Melinta Therapeutics Announces U.S. FDA Approval of supplemental new drug application for BAXDELA® (delafloxacin) for the treatment of community-acquired bacterial pneumonia (CABP). Melinta Therapeutics, Inc; 2019 [cited 2021 Dec 12]. Available from: http://ir.melinta.com/news-releases/news-release-details/melinta-therapeutics-announces-us-fda-approval-supplemental-news
   Google Scholar
• European Medicines Agency. EMEA-001080-PIP01-10 | European Medicines Agency. (europa.eu); [cited 2021 Dec 19]. Available from: https://www.ema.europa.eu/en/documents/smop-initial/chmp-summary-positive-opinion-quofenix_en-0.pdf
   Google Scholar
• European Medicines Agency. EMA/CHMP/99783/2021. Committee for Medicinal Products for Human Use (CHMP). Summary of opinion (postauthorisation). 2021 [cited 2021 Dec 19]. Available from: https://www.ema.europa.eu/en/documents/smop/chmp-post-authorisation-summary-positive-opinion-quofenix-ii-03_en.pdf
   Google Scholar
• Metersky ML, Masterton RG, Lode H, et al. Epidemiology, microbiology, and treatment considerations for bacterial pneumonia complicating influenza. Int J Infect Dis. 2012;16:e321–31.
   Google Scholar